Burney Co. Increases Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Burney Co. raised its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 19,823 shares of the specialty pharmaceutical company’s stock after purchasing an additional 377 shares during the quarter. Burney Co.’s holdings in Jazz Pharmaceuticals were worth $2,116,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Rise Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 2,255.6% during the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 203 shares in the last quarter. Versant Capital Management Inc boosted its holdings in shares of Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 269 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 116 shares in the last quarter. Gladius Capital Management LP purchased a new position in Jazz Pharmaceuticals during the 2nd quarter valued at about $33,000. Finally, Cape Investment Advisory Inc. boosted its stake in Jazz Pharmaceuticals by 14,600.0% during the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock worth $36,000 after acquiring an additional 292 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ traded down $0.33 during trading hours on Thursday, hitting $116.04. The stock had a trading volume of 97,684 shares, compared to its average volume of 662,345. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $146.70. The stock has a fifty day moving average price of $109.22 and a 200 day moving average price of $112.90. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 1.90. The firm has a market capitalization of $7.32 billion, a PE ratio of 23.99, a PEG ratio of 1.76 and a beta of 0.58.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on JAZZ shares. HC Wainwright reiterated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Needham & Company LLC lowered their price target on Jazz Pharmaceuticals from $208.00 to $205.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. Piper Sandler reduced their price objective on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a research note on Thursday, August 1st. Finally, StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $173.07.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.